325 related articles for article (PubMed ID: 32398057)
1. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
[TBL] [Abstract][Full Text] [Related]
2. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
Boiron L; Joura E; Largeron N; Prager B; Uhart M
BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
4. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
Prem K; Choi YH; Bénard É; Burger EA; Hadley L; Laprise JF; Regan MC; Drolet M; Sy S; Abbas K; Portnoy A; Kim JJ; Brisson M; Jit M
BMC Med; 2023 Aug; 21(1):313. PubMed ID: 37635227
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China.
Mo X; Gai Tobe R; Wang L; Liu X; Wu B; Luo H; Nagata C; Mori R; Nakayama T
BMC Infect Dis; 2017 Jul; 17(1):502. PubMed ID: 28720082
[TBL] [Abstract][Full Text] [Related]
6. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
Falcaro M; Soldan K; Ndlela B; Sasieni P
BMJ; 2024 May; 385():e077341. PubMed ID: 38749552
[TBL] [Abstract][Full Text] [Related]
7. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
8. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
Inturrisi F; Lissenberg-Witte BI; Veldhuijzen NJ; Bogaards JA; Ronco G; Meijer CJLM; Berkhof J
Int J Cancer; 2021 Jan; 148(2):320-328. PubMed ID: 32663316
[TBL] [Abstract][Full Text] [Related]
9. Public health impact of 2-, 4-, and 9-valent HPV vaccination in females on cervical and noncervical diseases in men and women under different coverage scenarios in China: A simulation study.
Diakite I; Kyle J; Situ S; Bai P; Zhang X; Wang W; Daniels V
Hum Vaccin Immunother; 2023 Aug; 19(2):2258569. PubMed ID: 37787054
[TBL] [Abstract][Full Text] [Related]
10. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Gingras G; Jit M; Boily MC; Bloem P; Brisson M
Lancet Public Health; 2023 Oct; 8(10):e788-e799. PubMed ID: 37777288
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination.
Ng SS; Hutubessy R; Chaiyakunapruk N
Vaccine; 2018 May; 36(19):2529-2544. PubMed ID: 29625764
[TBL] [Abstract][Full Text] [Related]
12. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
Falcaro M; Castañon A; Ndlela B; Checchi M; Soldan K; Lopez-Bernal J; Elliss-Brookes L; Sasieni P
Lancet; 2021 Dec; 398(10316):2084-2092. PubMed ID: 34741816
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.
Mahumud RA; Alam K; Keramat SA; Ormsby GM; Dunn J; Gow J
PLoS One; 2020; 15(6):e0233499. PubMed ID: 32484811
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.
Shiko Y; Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
BMC Infect Dis; 2020 Nov; 20(1):808. PubMed ID: 33153446
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment.
Qendri V; Bogaards JA; Baussano I; Lazzarato F; Vänskä S; Berkhof J
Lancet Public Health; 2020 Nov; 5(11):e592-e603. PubMed ID: 33120045
[TBL] [Abstract][Full Text] [Related]
16. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Lehtinen M; Söderlund-Strand A; Vänskä S; Luostarinen T; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Mar; 142(5):949-958. PubMed ID: 29055031
[TBL] [Abstract][Full Text] [Related]
17. Health impact and cost effectiveness of implementing gender-neutral HPV vaccination in Japan.
Palmer C; Tobe K; Negishi Y; You X; Chen YT; Abe M
J Med Econ; 2023; 26(1):1546-1554. PubMed ID: 37962015
[TBL] [Abstract][Full Text] [Related]
18. The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach.
Chanthavilay P; Reinharz D; Mayxay M; Phongsavan K; Marsden DE; Moore L; White LJ
BMC Health Serv Res; 2016 Aug; 16(1):418. PubMed ID: 27549921
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
Ribassin-Majed L; Lounes R; Clémençon S
PLoS One; 2012; 7(3):e32251. PubMed ID: 22427828
[TBL] [Abstract][Full Text] [Related]
20. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]